Introduced:
May 8, 2025
Policy Area:
Health
Congress.gov:
Bill Statistics
2
Actions
2
Cosponsors
1
Summaries
1
Subjects
1
Text Versions
Yes
Full Text
AI Summary
AI Summary
No AI Summary Available
Click the button above to generate an AI-powered summary of this bill using Claude.
The summary will analyze the bill's key provisions, impact, and implementation details.
Error generating summary
Latest Action
May 8, 2025
Read twice and referred to the Committee on Finance.
Summaries (1)
Introduced in Senate
- May 8, 2025
00
<p><strong>Access to Prescription Digital Therapeutics Act of </strong><strong>2025</strong></p><p>This bill provides for Medicare and Medicaid coverage of prescription digital therapeutics (i.e., software applications that are used to prevent, manage, or treat medical conditions). The Centers for Medicare & Medicaid Services must establish a Medicare payment methodology for payments to manufacturers that takes into account certain factors (e.g., ongoing use); manufacturers must report specified information about private payors, subject to civil penalties.</p>
Actions (2)
Read twice and referred to the Committee on Finance.
Type: IntroReferral
| Source: Senate
May 8, 2025
Introduced in Senate
Type: IntroReferral
| Source: Library of Congress
| Code: 10000
May 8, 2025
Subjects (1)
Health
(Policy Area)
Cosponsors (2)
(D-NJ)
Jul 15, 2025
Jul 15, 2025
(D-NH)
May 8, 2025
May 8, 2025
Full Bill Text
Length: 8,054 characters
Version: Introduced in Senate
Version Date: May 8, 2025
Last Updated: Nov 15, 2025 2:14 AM
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 1702 Introduced in Senate
(IS) ]
<DOC>
119th CONGRESS
1st Session
S. 1702
To amend titles XVIII and XIX of the Social Security Act to provide for
coverage of prescription digital therapeutics under such titles, and
for other purposes.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
May 8, 2025
Mrs. Capito (for herself and Mrs. Shaheen) introduced the following
bill; which was read twice and referred to the Committee on Finance
_______________________________________________________________________
A BILL
To amend titles XVIII and XIX of the Social Security Act to provide for
coverage of prescription digital therapeutics under such titles, and
for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
[From the U.S. Government Publishing Office]
[S. 1702 Introduced in Senate
(IS) ]
<DOC>
119th CONGRESS
1st Session
S. 1702
To amend titles XVIII and XIX of the Social Security Act to provide for
coverage of prescription digital therapeutics under such titles, and
for other purposes.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
May 8, 2025
Mrs. Capito (for herself and Mrs. Shaheen) introduced the following
bill; which was read twice and referred to the Committee on Finance
_______________________________________________________________________
A BILL
To amend titles XVIII and XIX of the Social Security Act to provide for
coverage of prescription digital therapeutics under such titles, and
for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1.
This Act may be cited as the ``Access to Prescription Digital
Therapeutics Act of 2025''.
SEC. 2.
THE MEDICARE PROGRAM.
(a) Prescription Digital Therapeutic Defined.--
(a) Prescription Digital Therapeutic Defined.--
Section 1861 of the
Social Security Act (42 U.
Social Security Act (42 U.S.C. 1395x) is amended by adding at the end
the following new subsection:
``
(nnn) Prescription Digital Therapeutic.--The term `prescription
digital therapeutic' means a product, device, internet application, or
other technology that--
``
(1) is cleared or approved under
the following new subsection:
``
(nnn) Prescription Digital Therapeutic.--The term `prescription
digital therapeutic' means a product, device, internet application, or
other technology that--
``
(1) is cleared or approved under
section 510
(k) ,
513
(f)
(2) , or 515 of the Federal Food, Drug, and Cosmetic Act;
``
(2) has a cleared or approved indication for the
prevention, management, or treatment of a medical disease,
condition, or disorder;
``
(3) primarily uses software to achieve its intended
result; and
``
(4) is a device that is exempt from
(k) ,
513
(f)
(2) , or 515 of the Federal Food, Drug, and Cosmetic Act;
``
(2) has a cleared or approved indication for the
prevention, management, or treatment of a medical disease,
condition, or disorder;
``
(3) primarily uses software to achieve its intended
result; and
``
(4) is a device that is exempt from
section 502
(f)
(1) of
the Federal Food, Drug, and Cosmetic Act under
(f)
(1) of
the Federal Food, Drug, and Cosmetic Act under
section 801.
of title 21 of the Code of Federal Regulations (or any
successor regulation).''.
(b) Coverage as Medical and Other Health Service.--
successor regulation).''.
(b) Coverage as Medical and Other Health Service.--
Section 1861
(s)
(2) of the Social Security Act (42 U.
(s)
(2) of the Social Security Act (42 U.S.C. 1395x
(s)
(2) ) is
amended--
(1) in subparagraph
(II) , by striking ``and'' at the end;
(2) in subparagraph
(JJ) , by adding ``and'' at the end; and
(3) by adding at the end the following new subparagraph:
``
(KK) prescription digital therapeutics furnished on or
after January 1, 2026;''.
(c) Requirements for Prescription Digital Therapeutics Under
Medicare.--Part B of the Social Security Act (42 U.S.C. 1395j et seq.)
is amended by inserting after
section 1834A the following new section:
``
``
SEC. 1834B.
``
(a) Payment.--
``
(1) In general.--Not later than 1 year after the date of
enactment of this section, the Secretary shall establish a
payment methodology for manufacturers of prescription digital
therapeutics, which may consist of a one-time payment or
periodic payments, as determined appropriate by the Secretary.
``
(2) Considerations for payment methodology.--For purposes
of establishing the payment methodology under paragraph
(1) ,
the Secretary shall consider--
``
(A) the actual list charge of such prescription
digital therapeutic;
``
(B) the weighted median (calculated by arraying
the distribution of all payment rates reported for the
most recent period for which such rates were reported
under subsection
(c) (1) for each prescription digital
therapeutic weighted by volume for each payor and each
manufacturer) for such prescription digital
therapeutic;
``
(C) in the case of a prescription digital
therapeutic that requires ongoing use, the amount for
such ongoing use; and
``
(D) other factors as determined by the Secretary.
``
(b) Coding.--
``
(1) In general.--Not later than 2 years after the date of
enactment of this section, the Secretary shall establish
product-specific HCPCS codes for prescription digital
therapeutic covered under this title.
``
(2) Temporary code.--The Secretary shall adopt temporary
product-specific HCPCS codes for purposes of providing payment
under this title until a permanent product-specific HCPCS code
has been established under paragraph
(1) .
``
(c) Manufacturer Reporting.--
``
(1) In general.--Beginning on January 1, 2026, each
manufacturer of a prescription digital therapeutic covered
under this title shall submit to the Secretary, at such time
and in such manner as specified by the Secretary, and annually
thereafter, a report describing--
``
(A) the payment rate that was paid by each
private payor for each prescription digital therapeutic
during the period specified by the Secretary;
``
(B) the volume of such prescription digital
therapeutic distributed to each such payor for such
period; and
``
(C) the number of individual users of such
prescription digital therapeutic for such period.
``
(2) Treatment of discounts.--The payment rate reported by
a manufacturer in accordance with paragraph
(1)
(A) shall
reflect all discounts, rebates, coupons, and other price
concessions, including those described in
section 1847A
(c) (3) .
(c) (3) .
``
(3) Civil monetary penalty.--
``
(A) In general.--If the Secretary determines that
a manufacturer has failed to report, or made a
misrepresentation or omission in reporting, information
under this subsection with respect to a prescription
digital therapeutic, the Secretary may apply a civil
money penalty in an amount of up to $10,000 per day for
each failure to report or each such misrepresentation
or omission.
``
(B) Application.--The provisions of
``
(3) Civil monetary penalty.--
``
(A) In general.--If the Secretary determines that
a manufacturer has failed to report, or made a
misrepresentation or omission in reporting, information
under this subsection with respect to a prescription
digital therapeutic, the Secretary may apply a civil
money penalty in an amount of up to $10,000 per day for
each failure to report or each such misrepresentation
or omission.
``
(B) Application.--The provisions of
section 1128A
(other than subsections
(a) and
(b) ) shall apply to a
civil money penalty under this paragraph in the same
manner as they apply to a civil money penalty or
proceeding under
(other than subsections
(a) and
(b) ) shall apply to a
civil money penalty under this paragraph in the same
manner as they apply to a civil money penalty or
proceeding under
(a) and
(b) ) shall apply to a
civil money penalty under this paragraph in the same
manner as they apply to a civil money penalty or
proceeding under
section 1128A
(a) .
(a) .
``
(4) Confidentiality.--Information reported under this
subsection shall be treated in the same manner in which
information disclosed by a manufacturer or a wholesaler of a
covered outpatient drug is treated under
section 1927
(b)
(3)
(D) .
(b)
(3)
(D) .
``
(d) === Definitions. ===
-For purposes of this section:
``
(1) Actual list charge.--The term `actual list charge'
means the publicly available payment rate for a prescription
digital therapeutic on the first day that such prescription
digital therapeutic is available for purchase by a private
payor.
``
(2) HCPCS.--The term `HCPCS' means, with respect to an
item, the code under the Healthcare Common Procedure Coding
System
(HCPCS) (or a successor code) for such item.
``
(3) Manufacturer.--The term `manufacturer' has the
meaning given such term by
section 820.
(o) of title 21, Code
of Federal Regulations (or any successor regulation).
``
(4) Prescription digital therapeutic.--The term
`prescription digital therapeutic' has the meaning given such
term in
section 1861
(nnn) .
(nnn) .
``
(5) Private payor.--The term `private payor' has the
meaning given such term in
section 1834A
(a)
(8) .
(a)
(8) .''.
SEC. 3.
MEDICAID PROGRAM.
Section 1905
(a) of the Social Security Act (42 U.
(a) of the Social Security Act (42 U.S.C. 1396d
(a) ) is
amended--
(1) in paragraph
(31) , by striking ``; and'' and inserting
a semicolon;
(2) by redesignating paragraph
(32) as paragraph
(33) ; and
(3) by inserting the following paragraph after paragraph
(31) :
``
(32) prescription digital therapeutics (as defined in
section 1861
(nnn) ); and''.
(nnn) ); and''.
<all>